The Use of Small Peptides in the Diagnosis and Treatment of Hepatocellular Carcinoma

Tsang, Felice Ho‐Ching; Lee, Nikki P.; Luk, John M.

doi:10.2174/092986609788167860

Cited by 6 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peptides, by virtue of their small size, possess a number of unique features defining them as promising therapeutic agents that include effective tissue penetration as well as negligence to the host immune system leading to lesser or no off-target effects and adverse effects [290]. Some of the studied peptides in HCC include SP94 [291][292][293], Tv1 [294][295][296][297], FFW [298,299], iRGD [83,91,300], GG-8-6 [301], BR2 [302,303], β3 [304], GW-H1 [305,306], bovicin HC5 [307], R-Tf-D-LP4 [308], C7 [309], HCC79 [289,310], GPC3 peptide [311][312][313] and cecropinXJ [290,314]. Peptides are also being investigated in HCC vaccine development, targeting specifically overexpressed targets such as GPC3 [315].…”

Section: Emerging Use Of Peptides In Hcc Therapy As An Evolutionary Improvement In Hcc Nanomedicinementioning

confidence: 99%

Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment

2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2–9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of improving the safety and efficacy of treatment for HCC. Although remarkable success has been achieved in nanomedicine research, there are unique considerations such as molecular heterogeneity and concomitant liver dysfunction that complicate the translation of nanotheranostics in HCC. This review highlights the progress, challenges, and targeting opportunities in HCC nanomedicine based on the growing literature in recent years.

show abstract

Section: Emerging Use Of Peptides In Hcc Therapy As An Evolutionary Improvement In Hcc Nanomedicinementioning

confidence: 99%

Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment

2021

View full text Add to dashboard Cite

show abstract

Discovery of Lamin B1 and Vimentin as Circulating Biomarkers for Early Hepatocellular Carcinoma

Wong

Luk

2012

Liver Proteomics

View full text Add to dashboard Cite

The recent advancements in proteomic technologies have reconstituted our research strategies over different type of liver diseases including hepatocellular carcinoma (HCC). Combined analyses on HCC proteome and clinicopathological data of patients have allowed identification of many promising biomarkers that can be further developed into noninvasive diagnostic assays for cancer surveillance. Capitalizing our established proteomic platform primarily based on two-dimensional polyacrylamide gel electrophoresis (2DE) and MALDI-TOF/TOF mass spectrometry, our groups have identified lamin B1 (LMNB1) and vimentin (VIM) as promising biomarkers for detection of early HCC. Protein levels of both biomarkers were significantly elevated in cancerous tissues when compared to the controls in disease-free and cirrhotic liver subjects. Further investigation of the circulating LMNB1 mRNA level in patients' blood samples by standard PCR showed 76% sensitivity and 82% specificity for detection of early HCC. In parallel, an ELISA assay for measuring circulating vimentin level in patients' serum samples could detect small HCC at 40.91% sensitivity and 87.5% specificity. The candidate biomarkers were evaluated with the diagnostic performance of α-fetoprotein (AFP) for HCC. In this article, we address the current protocols for HCC biomarker discovery, ranging from clinical sample preparation, 2DE proteomic profiling and informatics analysis, and assay development and clinical validation study. Focus is emphasized on the methods for sample preservation and low-abundance protein enrichment.

show abstract

MicroRNA as Cancer Biomarkers and Targets

Wong

Jiang

Luk

2013

New Advances on Disease Biomarkers and Molecular Targets in Biomedicine

View full text Add to dashboard Cite

The Use of Small Peptides in the Diagnosis and Treatment of Hepatocellular Carcinoma

Cited by 6 publications

References 62 publications

Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment

Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment

Discovery of Lamin B1 and Vimentin as Circulating Biomarkers for Early Hepatocellular Carcinoma

MicroRNA as Cancer Biomarkers and Targets

Contact Info

Product

Resources

About